Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Overview of attention for article published in Drug Design, Development and Therapy, August 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

patent: 9 patents
googleplus: 1 Google+ user

Citations

dimensions_citation: 438 Dimensions

Readers on

mendeley: 349 Mendeley

Summary News X Patents Google+ Dimensions citations

So far, Altmetric has seen 1 Google+ post.

Dove Medical Press (NZ) Ltd, 18 Aug 2015

Clinical development of galunisertib Abstract: Transforming growth factor-beta (TGF-β) signaling regulates... Clinical…